# Akamis Bio

Source: https://onco.cc/companies/akamis-bio/  
OnCo record `akamis-bio` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Akamis Bio develops cancer-killing viruses, given into a vein, that are built to carry extra immune-stimulating genes into tumours. It is focused on bowel cancer, first in locally advanced rectal cancer.

## Summary

Akamis Bio develops T-SIGn therapeutics: intravenously given, tumour-selective oncolytic adenoviruses (based on a chimeric group B adenovirus, enadenotucirev) that carry transgene payloads into tumour cells. Its lead programme, NG-350A, encodes a secreted CD40 agonist antibody and is being tested with chemoradiotherapy in mismatch-repair-proficient locally advanced rectal cancer in the phase 1b FORTRESS trial (NCT06459869), which the company says is fully enrolled with topline results expected in the first half of 2027; the company reports an FDA Fast Track designation for NG-350A in this setting. NG-348, which encodes membrane-bound CD80 and an anti-CD3 single-chain antibody fragment, completed a phase 1 study in advanced epithelial tumours and is listed for metastatic colorectal cancer. A third, undisclosed programme uses T-SIGn to support CAR-T therapy in solid tumours with an undisclosed partner. In December 2024 the company announced $60 million in funding linked to a Series A Prime round led by Sedgwick Yard and a licence granting Xuanzhu Biopharma Greater China rights to NG-350A. The company has offices in Cambridge, Massachusetts and Oxford, UK.

## Fields

- Kind: Company
- Last checked: 2026-11-04
- Also known as: Akamis Bio, Inc.
- HQ: Cambridge, MA
- Type: biotech
- Website: https://www.akamisbio.com/

## Notes

- Founding year not stated on the company's site; omitted.
- Secondary sources (trade press) say Akamis Bio was formerly PsiOxus Therapeutics, renamed in January 2023; the primary Business Wire release refused a script, so the former name is not added as an alias. ClinicalTrials.gov lists Akamis Bio as sponsor of enadenotucirev, NG-641 and NG-350A trials from 2012 onward.
- No ClinicalTrials.gov record was found for the NG-348 phase 1 study by name search.
- None of the company's trials are yet OnCo trial records, so no trials are linked.
- The $60 million December 2024 figure is described by the company as funding linked to a Series A Prime financing and a licensing deal together, so it is not entered as a single equity round.

## Sources

- Official website: https://www.akamisbio.com/
- Pipeline page: https://www.akamisbio.com/science-pipeline/pipeline/
- FORTRESS clinical trial page: https://www.akamisbio.com/patient-community/clinical-trials/
- Press release: $60 million Series A Prime and Xuanzhu licence (17 Dec 2024): https://www.akamisbio.com/news/akamis-bio-announces-60-million-in-funding-linked-to-series-a-prime-financing-and-new-strategic-partnership/
- Press release: NG-348 phase 1 data at SITC 2026 (3 Nov 2026): https://www.akamisbio.com/news/akamis-bio-to-present-data-from-a-phase-1-study-of-ng-348-in-patients-with-advanced-epithelial-tumors-at-sitc-2026/
- ClinicalTrials.gov NCT06459869 (FORTRESS): https://clinicaltrials.gov/study/NCT06459869
- ARCH Venture Partners portfolio entry (archived 16 Oct 2026): https://web.archive.org/web/20261016142320/https://www.archventure.com/portfolio/

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- fronts: [Immunotherapy](https://onco.cc/fronts/immunotherapy/)
- technologies: [Oncolytic viruses](https://onco.cc/technologies/oncolytic-virus/)
- targets: [CD3](https://onco.cc/targets/cd3/), [CD40](https://onco.cc/targets/cd40/), [CD80 (B7-1)](https://onco.cc/targets/cd80/)
- drugs: [NG-348](https://onco.cc/drugs/ng-348/), [NG-350A](https://onco.cc/drugs/ng-350a/)
- companies: [ARCH Venture Partners](https://onco.cc/companies/arch-venture-partners/)
- trials: [First in Human Study of NG-350A (an Oncolytic Adenoviral Vector Which Expresses an Anti-CD40 Antibody)](https://onco.cc/trials/nct03852511/), [NG-350A Plus Chemoradiotherapy for Locally Advanced Rectal Cancer](https://onco.cc/trials/nct06459869/), [Study of NG-350A Plus Pembrolizumab in Metastatic or Advanced Epithelial Tumours (FORTIFY)](https://onco.cc/trials/nct05165433/)

---
JSON: https://onco.cc/api/v1/entities/akamis-bio.json